Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany..
BACKGROUND: In real-world studies, it is unclear whether galcanezumab has a significant effect in the first week after administration.
METHODS: We retrospectively assessed 55 high-frequency episodic migraine (HFEM) and chronic migraine patients who received three galcanezumab doses. Mean changes in the numbers of weekly migraine days (WMDs) during month 1 and migraine days per month (MMDs) after 1-3 months of treatment were obtained. Clinical factors related to a ≥ 50% response rate (RR) at month 3 were analyzed. The prediction of ≥ 50% responders at month 3 using different weekly RRs at week 1 (W1) was evaluated. The RR at W1 was calculated with the following formula: RR (%) = 100 - [(WMDs at W1/baseline WMD) × 100].
RESULTS: The number of MMDs significantly improved from baseline to 1, 2 and 3 months. The ≥ 50% RR was 50.9% at 3 months. The number of WMDs decreased significantly from baseline to week 1 (- 1.6 ± 1.7 days), week 2 (- 1.2 ± 1.6 days), week 3 (- 1.0 ± 1.3 days), and week 4 (- 1.1 ± 1.6 days) during month 1. The RR at W1 was largest (44.6 ± 42.2%). The ≥ 30%, ≥ 50% and ≥ 75% RRs at W1 were significantly predictive of a ≥ 50% RR at 3 months. Logistic regression analysis predicting a ≥ 50% RR at month 3 showed that the RR at W1 was the sole contributing factor.
CONCLUSION: In our study, galcanezumab showed a significant effect in the first week after administration, and the RR at W1 could predict the RR at 3 months.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:270 |
|---|---|
| Enthalten in: |
Journal of neurology - 270(2023), 9 vom: 15. Sept., Seite 4377-4384 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suzuki, Keisuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
55KHL3P693 |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 27.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00415-023-11788-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357220447 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357220447 | ||
| 003 | DE-627 | ||
| 005 | 20231229124113.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00415-023-11788-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM357220447 | ||
| 035 | |a (NLM)37219606 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suzuki, Keisuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 27.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. | ||
| 520 | |a BACKGROUND: In real-world studies, it is unclear whether galcanezumab has a significant effect in the first week after administration | ||
| 520 | |a METHODS: We retrospectively assessed 55 high-frequency episodic migraine (HFEM) and chronic migraine patients who received three galcanezumab doses. Mean changes in the numbers of weekly migraine days (WMDs) during month 1 and migraine days per month (MMDs) after 1-3 months of treatment were obtained. Clinical factors related to a ≥ 50% response rate (RR) at month 3 were analyzed. The prediction of ≥ 50% responders at month 3 using different weekly RRs at week 1 (W1) was evaluated. The RR at W1 was calculated with the following formula: RR (%) = 100 - [(WMDs at W1/baseline WMD) × 100] | ||
| 520 | |a RESULTS: The number of MMDs significantly improved from baseline to 1, 2 and 3 months. The ≥ 50% RR was 50.9% at 3 months. The number of WMDs decreased significantly from baseline to week 1 (- 1.6 ± 1.7 days), week 2 (- 1.2 ± 1.6 days), week 3 (- 1.0 ± 1.3 days), and week 4 (- 1.1 ± 1.6 days) during month 1. The RR at W1 was largest (44.6 ± 42.2%). The ≥ 30%, ≥ 50% and ≥ 75% RRs at W1 were significantly predictive of a ≥ 50% RR at 3 months. Logistic regression analysis predicting a ≥ 50% RR at month 3 showed that the RR at W1 was the sole contributing factor | ||
| 520 | |a CONCLUSION: In our study, galcanezumab showed a significant effect in the first week after administration, and the RR at W1 could predict the RR at 3 months | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Calcitonin gene-related peptide | |
| 650 | 4 | |a Galcanezumab | |
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a Weekly migraine days | |
| 650 | 7 | |a galcanezumab |2 NLM | |
| 650 | 7 | |a 55KHL3P693 |2 NLM | |
| 700 | 1 | |a Suzuki, Shiho |e verfasserin |4 aut | |
| 700 | 1 | |a Shiina, Tomohiko |e verfasserin |4 aut | |
| 700 | 1 | |a Haruyama, Yasuo |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Funakoshi, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Hirata, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology |d 1974 |g 270(2023), 9 vom: 15. Sept., Seite 4377-4384 |w (DE-627)NLM000508543 |x 1432-1459 |7 nnns |
| 773 | 1 | 8 | |g volume:270 |g year:2023 |g number:9 |g day:15 |g month:09 |g pages:4377-4384 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00415-023-11788-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 270 |j 2023 |e 9 |b 15 |c 09 |h 4377-4384 | ||